Company
Nuformix PLC
LON:NFX
Nuformix PLC is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
51 stories
Nuformix showcases proprietary tranilast programme to potential licensing partners
Pre-clinical update underlines progress for company’s NXP002 programme
Nuformix makes headway with lead asset as it continues to build 'robust data package'
Pre-clinical drug NXP002 is being developed to treat idiopathic pulmonary fibrosis
Nuformix appoints former CEO Dan Gooding as exec director, Julian Gilbert as non-exec chairman
Gooding is a co-founder of Nuformix and was its CEO until June 2020
Nuformix gets two presentations approved for leading international respiratory congress
The event is attended by all the major respiratory-focused pharmaceutical companies
Nuformix hoping to develop a 'bio-better' version of AstraZeneca blockbuster
The company is working on an enhanced formulation of AstraZeneca's cancer drug Lynparza
Nuformix initiates inhalation studies using new delivery method
Results are expected to be generated throughout the second half of 2022 as development milestones are achieved
Nuformix chairman resigns to take up new role
Dr Alastair Riddell is departing with immediate effect
Nuformix updates on NXP002, drug pipeline and CEO search
The company provided a comprehensive overview of its prospects
Nuformix will receive a gross £1.32mln from second tranche of Lanstead funding agreement
The proceeds will be invested in further research and development work on Nuformix’s drug candidates NXP002 and NXP004
Nuformix says patent application for reformulated AstraZeneca blockbuster has progressed to publication phase
“We believe NXP004 has significant potential and look forward to the granting of the patent in due course,” said Nuformix chairman Alastair Riddell
Nuformix appoints former CEO Dan Gooding as consultant
Gooding instigated the company’s NXP002 programme, which is an inhaled therapy for treating Idiopathic Pulmonary Fibrosis
Nuformix hails progress partner is making with reformulated anti-sickness drug
Oxilio is working with Quotient Sciences, a drug development and manufacturing accelerator
Nuformix raises £1.65mln to fund R&D and business development work
It has inked a subscription agreement with Lannstead Capital
Nuformix aiming to get NXP002 into clinic by end of 2022
The company released strong pre-clinical date earlier this week
Nuformix 'delighted' with preclinical data for lead lung scarring treatment
The company is a specialist in repurposing drugs already on the market for new indications
Nuformix files patent for improved formulation of a £1bn blockbuster drug
NXP004 could provide an advance on an already successful unnamed treatment
Nuformix signs up Oxilio to develop NXP001 oncology asset
Achieving this exclusive global licensing deal for NXP001 in oncology is a major step forward, says chief executive Dr Anne Brindley
Nuformix CEO to step down
The firm said Anne Brindley will continue in her current position for the next six months and has committed to assist the company with an orderly transition
Nuformix says drug pipeline is 'building momentum'
Negotiations are underway about a global license deal for one drug asset to treat the side-effects of chemotherapy
Nuformix secures US patent allowance for NXP002 asset
CEO Anne Brindley said the allowance notice means the patent will proceed to be issued and is an “important endorsement” of the company’s discoveries
Nuformix making progress on three fronts
The company was updating on plans first outlined in March - at the time of its over-subscribed City fundraiser
Nuformix appoints Dr Alastair Riddell as non-exec chair, following reshuffle
"I am delighted to be able to join Nuformix as it develops its portfolio of newly formulated established products for new and important therapeutic indications," said Alastair Riddell
Nuformix eyes big opportunity with new forms of fibrosis and cancer drugs
By developing new forms of safe drugs, the company generates its own intellectual property and may shorten the timeline to market
Nuformix PLC CEO outlines how new funds will help propel the company and its portfolio to the next level
Dr Anne Brindley was speaking after the company said it had conditionally raised just under £1.6mln
Nuformix CEO says £1.6mln of new funding will help take lead asset to 'next value inflexion point'
The proceeds will be put to work developing the portfolio of opportunities, including lead candidate NXP002 for idiopathic pulmonary fibrosis
Nuformix looks to broaden reach of key drug developments
Oxilio took out an option on NXP001 in oncology in September
Nuformix boosts coffers to support ambitious growth plans; looks to target COVID-19 indications for its assets
"The board is positive about the opportunities for the group, in particular, for the development of certain assets for the treatment of Covid-19. Support for these efforts will require additional business development resource”
Nuformix grants six month option over cancer drug candidate
If the option is triggered, Nuformix will receive a “significant upfront payment”, additional development milestones and a royalty on net sales
Nuformix takes conservative path on cancer and IPF developments
In oncology, Nuformix has granted Oxilio a six-month option over NXP001
Nuformix encouraged by pre-clinical data from IPF candidate
"Whilst this is only the pilot phase of this pre-clinical study, positive indications of anti-fibrotic activity are very encouraging."
Nuformix says there has been increased interest in its assets and their potential to treat COVID-19
“These business discussions are confidential and further announcements will be made as and when appropriate,” investors were told
Nuformix announces resignation of chief executive
The firm’s chairman, Christopher Blackwell, will lead the company as executive chairman until a successor is found
Nuformix inks development agreement; business remains resilient during lockdown
Chief executive, Dr Dan Gooding said last year’s £1.25mln fundraise and the business’ low operating costs, meant the firm was “well-placed to ride out the current worldwide issues”
Archive
PureTech Health lifted by conference news
A look at today's movers on the London Stock Exchange
Nuformix still awaiting payment from Chinese partner
Nuformix noted that its primary contact at Newsummit was dismissed in January
Archive
Proactive news snapshot: Nuformix, Polarean Imaging, Nektan, CentralNic …
A glance at some of the day's highlights from the Proactive Investors newswire
Nuformix continues to explore additional development opportunities
"We have achieved significant progress during the period, both operationally and within our lead programmes," said Dan Gooding, Nuformix's CEO
Nuformix says it has a "good shot" at doing something "really meaningful" with lung disease drug
The company represents a departure from the traditional small-cap drug development company that’s normally a binary bet on a university-discovered compound. Instead, it takes small molecule (pharmaceutical) drugs that are already on the mar
Nuformix: Repurposing small molecule drugs for patients and investors
Nuformix re-engineers a drug’s crystalline form by adding a molecule that improves it